The Lupus Research Alliance celebrates our annual Breaking through Lupus Gala on November 25, 2019 at the Ziegfeld Ballroom – an iconic landmark mingling up-to-the-moment elegance with the art-deco grandeur of 1920’s movie palaces. This year we are proud to honor Alfred F. Kelly, Chairman and Chief Executive Officer, Visa Inc. and Molly McCabe, Co-Founder, […] READ MORE
October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] READ MORE
September 26, 2019 In a newly published Michigan study, nearly 1 in 3 adults with systemic lupus erythematosus used prescription opioids to treat pain despite lack of evidence that opioids effectively reduce pain from lupus and rheumatic diseases. As people with lupus know only too well, symptoms of the disease commonly include pain in the […] READ MORE
September 24, 2019 The Accelerating Medicines Partnership (AMP) RA/Lupus Program, a joint effort involving the National Institutes of Health (NIH), the Foundation for NIH, pharmaceutical companies, and non-profit organizations such as the Lupus Research Alliance, has reached a milestone, finishing an important phase of its studies. Researchers with the AMP RA/Lupus Program have published a […] READ MORE
September 24, 2019 Interleukin-2 at a low-dose may be effective in treating lupus, according to newly published results of a double-blind and placebo-controlled clinical trial. In this trial, 60 patients received either Interleukin-2 at a low dose of 1 million IU or placebo along with standard treatment for 12 weeks. The primary endpoint – the […] READ MORE
September 19, 2019 A small clinical trial published in Lupus Science & Medicine found that taking vitamin D supplements did not improve bone health for people with lupus. Conducted by several lupus experts throughout the U.S., the study looked at the effect of vitamin D supplements on changes in bone turnover markers that indicate changes […] READ MORE
September 18, 2019 The LRA is pleased to share that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to obinutuzumab (Gazyva®) for adults with lupus nephritis – the most common complication of lupus. The FDA’s designation aims to speed up the development and review of drugs intended to treat a serious condition […] READ MORE
September 19, 2019 Treating patients with lupus until they reach specific health goals can reduce disease flares and prevent organ damage, according to a research team co-led by Professor Eric F. Morand, at Monash University in Australia and past recipient of the Distinguished Innovator Award from the Lupus Research Alliance (LRA). This study is important […] READ MORE
A new study partly funded by the Lupus Research Alliance (LRA) may help explain how the immune system attacks patients’ DNA in lupus. Together with the laboratory of Dr. David Raulet at the University of California, Berkeley, Dr. Joshua Woodward of the University of Washington in Seattle and his colleagues discovered a protein door in […] READ MORE
Over the past five years, the Rally Against Lupus event raised serious funds for lupus research, totaling over $3.6 million! Please continue to support and help further lupus research, so we can find a cure for lupus. Join Us! READ MORE
September 5, 2019 Lupus Research Alliance Research Committee member, Dr. Mark Davis (Stanford University), recently published an important paper in the highly prestigious journal Nature that may transform how scientists view autoimmune diseases, including lupus. Dr. Davis and his team studied a mouse model of multiple sclerosis (MS), an autoimmune disease in which the immune […] READ MORE
NEW YORK, NY. August 29 — The Lupus Research Alliance is excited to share the good news that a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study. Anifrolumab is a therapeutic antibody that blocks type I interferons, a molecule that promotes lupus inflammation. Over 15 studies […] READ MORE
